

Zeitschrift: Jahresbericht / Schweizerische Akademie der Medizinischen Wissenschaften = Rapport annuel / Académie suisse des sciences médicales = Rapporto annuale / Accademia svizzera delle scienze mediche

Herausgeber: Schweizerische Akademie der Medizinischen Wissenschaften

Band: - (1989)

Artikel: Molecular studies of retroviral replication : potential targets for therapeutic intervention

Autor: Skalka, Anna Marie

DOI: <https://doi.org/10.5169/seals-308358>

Nutzungsbedingungen

Die ETH-Bibliothek ist die Anbieterin der digitalisierten Zeitschriften auf E-Periodica. Sie besitzt keine Urheberrechte an den Zeitschriften und ist nicht verantwortlich für deren Inhalte. Die Rechte liegen in der Regel bei den Herausgebern beziehungsweise den externen Rechteinhabern. Das Veröffentlichen von Bildern in Print- und Online-Publikationen sowie auf Social Media-Kanälen oder Webseiten ist nur mit vorheriger Genehmigung der Rechteinhaber erlaubt. [Mehr erfahren](#)

Conditions d'utilisation

L'ETH Library est le fournisseur des revues numérisées. Elle ne détient aucun droit d'auteur sur les revues et n'est pas responsable de leur contenu. En règle générale, les droits sont détenus par les éditeurs ou les détenteurs de droits externes. La reproduction d'images dans des publications imprimées ou en ligne ainsi que sur des canaux de médias sociaux ou des sites web n'est autorisée qu'avec l'accord préalable des détenteurs des droits. [En savoir plus](#)

Terms of use

The ETH Library is the provider of the digitised journals. It does not own any copyrights to the journals and is not responsible for their content. The rights usually lie with the publishers or the external rights holders. Publishing images in print and online publications, as well as on social media channels or websites, is only permitted with the prior consent of the rights holders. [Find out more](#)

Download PDF: 26.03.2026

ETH-Bibliothek Zürich, E-Periodica, <https://www.e-periodica.ch>

MOLECULAR STUDIES OF RETROVIRAL REPLICATION

Potential targets for therapeutic intervention

ANNA MARIE SKALKA

The RNA tumor viruses (Retroviruses) have long been of interest to cancer researchers because they are known to cause disease in various animal species. Recently, there has been an increased sense of urgency in efforts to understand the molecular biology of these viruses due to the realization that some are also important human pathogens, causing both cancer (adult T cell leukemia) and AIDS.

AIDS is a progressive disease of the immune and central nervous systems. The course of this illness is closely coupled to virus replication. Disease symptoms in the late phase are correlated with a *decrease* in the number of CD4⁺ “helper” T lymphocytes (the host cell target of the virus), and an *increase* in concentration of viral proteins in the circulation. Thus, control or elimination of virus replication is a rational strategy for therapy in this disease.

Investigations of the retroviral replication cycle have focused not only on reactions and functions that are unique to the human viral strains, but also on steps that are common to all retroviruses. The latter studies profit from a substantial background of knowledge obtained through earlier work with the C-type retroviruses of rodent and avian species.

Two of the most promising areas of research aimed at the development of therapeutic agents are analysis of the virus-host cell attachment phenomenon, and studies of the mechanism of reactions catalyzed by the three essential viral enzymes. Understanding how the virus attaches to a sensitive cell is important to the design of potential vaccines and can suggest strategies for intervention *before* the virus enters a susceptible cell. The viral enzymes are particularly attractive targets for potential drugs that can block replication *after* the virus enters the cell.

The first wave of therapeutic agents that are available for clinical application includes inhibitors of the viral/enzyme reverse-transcriptase (RT),

which is responsible for the synthesis of viral DNA. The limited, but significant, efficacy of one inhibitor of RT, the drug AZT (3'Azido, 2' 3' dideoxythymidine) has encouraged additional efforts in this direction and more compounds of this type are in various stages of clinical testing. The two other viral enzyme targets are the integration protein (IN) and the viral protease (PR). IN is associated with an endonuclease activity that is required in the reaction which joins viral DNA to the host DNA. PR is responsible for cutting the long viral precursor proteins in newly formed particles into the smaller proteins and enzymes that are necessary for subsequent infection. PR has been under intensive study by many academic and industrial researchers. Recently, two retroviral PRs, from the avian Rous sarcoma virus (RSV) and the AIDS virus (HIV), have been crystallized. Molecular modeling and biochemical studies with these proteins suggest several approaches for the design of inhibitors which may soon be available for biological testing.

The situation today is significantly changed from that of only five years ago, when there were virtually no promising AIDS drugs. Now there is such a large number of potential candidates and diverse approaches that clinical testing programs will soon be saturated. Because of this, new yardsticks for establishing priorities for drug candidates and end points of efficacy, will have to be established. This hopeful note comes none to soon both for physicians and for AIDS victims who are predicted to number close to a million, worldwide, by 1991.